Table 1.
Patient characteristics
| Patients | N = 29 |
|---|---|
| Median age (range) - yrs | 59 (26 -- 80) |
| Gender -- no. (%) | |
| Male (%) | 15 (52.0) |
| Female (%) | 14 (48.0) |
| ECOG performance status -- no. (%) | |
| 0 | 11 (37.9) |
| 1 | 17 (58.6) |
| 2 | 1 (3.5) |
| Primary tumor site -- no. (%) | |
| Pancreas | 13 (44.8) |
| Functioning | 5 (17.2) |
| Unknown | 7 (24.2) |
| Small bowel | 7 (24.2) |
| Appendix | 1 (3.4) |
| Colon | 1 (3.4) |
| Tumor Stage -- no. (%) | |
| Locally advanced/metastatic | 2/27 |
| Site of metastases -- no. (%) | |
| < 2 sites | 13 (44.8) |
| ≥ 2 sites | 16 (55.2) |
| Prior therapies -- no. (%) | |
| Surgery | 9 (31.0) |
| Progressive disease | 29 (100) |
| Baseline symptoms -- no. (%) | |
| Diarrhea | 6 (20.6) |
| Flushing | 4 (13.8) |
| Carcinoid syndrome | 4 (13.8) |
| Hypoglycemia | 2 (6.9) |
| Others | 10 (34.5) |
| Circulating chromogranin A levels (U/L) - no. (%) | |
| Normal levels | 4 (13.8) |
| Supranormal levels | 25 (86.2) |
|
Histological tumor characteristics -- no. (%) SST2 |
|
| 1+ | 2 (9.1) |
| 2+ | 8 (36.4) |
| 3+ | 12 (54.5) |
| missing | 7 |
| Mitosis (per square millimeter) | |
| < 2 | 17 (68.0) |
| 2 -- 20 | 7 (28.0) |
| > 20 | 1 (4.0) |
| missing | 4 |
| Ki67 | |
| ≤ 2% | 11 (42.3) |
| 3 -- 10% | 13 (50.0) |
| > 10% | 2 (7.7) |
| missing | 3 |
| VEGF | |
| 0 | 3 (15.8) |
| 1 | 4 (21.1) |
| 2 | 7 (36.8) |
| 3 | 5 (26.8) |
| missing | 10 |
SST2 = somatostatin receptor type 2
VEGF = vascular endothelial growth factor